Related Experiment Video
Updated: Jul 30, 2025
12:23
Granulocyte-dependent Autoantibody-induced Skin Blistering
Published on: October 12, 2012
10.6K
Biological treatment for bullous pemphigoid
Meital Oren-Shabtai1,2, Daniel Mimouni1,2, Adi Nosrati1,2
1Division of Dermatology, Rabin Medical Center, Petah Tikva, Israel.
Frontiers in Immunology
|May 14, 2023
Summary
Biological therapies offer effective and safe treatment options for severe bullous pemphigoid (BP) unresponsive to conventional treatments. These novel approaches show significant clinical improvement and disease clearance in recalcitrant cases.
Area of Science:
- Dermatology
- Immunology
- Pharmacology
Background:
- Bullous pemphigoid (BP) is a common autoimmune blistering disease.
- Corticosteroids are first-line but have significant side effects.
- Adjuvant and biological therapies are explored for recalcitrant BP.
Purpose of the Study:
- Evaluate clinical and immunological features of patients with recalcitrant BP treated with biologics.
- Assess the efficacy and safety of these immunobiological therapies.
Main Methods:
- Retrospective analysis of nine adult BP patients from two centers.
- Patients received rituximab, omalizumab, or dupilumab.
- Clinical response and adverse events were analyzed.
Main Results:
- 78% of patients showed satisfactory clinical improvement; 55% achieved complete clearance.
- Rituximab, omalizumab, and dupilumab were used.
- No adverse events were reported during the study period.
Conclusions:
- Novel biological therapies are efficient and safe for steroid-dependent BP.
- These treatments are effective in patients unresponsive to conventional immunosuppressants.
Related Concept Videos
01:29Inflammatory Bowel Disease IV: Pharmacological Management
160
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
160
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
181
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
181
01:30Skin Cancer
4.3K
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
4.3K